Library / Retatrutide
Some human studies
Retatrutide
GLP-1, GIP and glucagon receptor agonist · Weight & GLP-1 · LY3437943
What it is
An experimental "triple agonist" that acts on three hormone receptors involved in appetite, blood sugar and energy use.
What research covers
In a phase 2 trial, people on the highest dose lost about 24% of their body weight on average over 48 weeks. Larger phase 3 trials (the TRIUMPH program) are under way. It is not approved anywhere at the time of writing.
Reported side effects
- Nausea, vomiting and diarrhoea
- Reduced appetite
- Increased heart rate in some trial participants
Not suitable for, or talk to a doctor first
- Personal or family history of medullary thyroid cancer or MEN2
- History of pancreatitis
- Pregnancy
Good to know
- Products sold online are not the trial medicine and are unregulated.
Legal status
| Australia | Not an approved medicine in Australia. Peptides like this are generally prescription-only (Schedule 4) and need a prescription to import. Check current rules with the TGA. |
|---|---|
| United States | Investigational. Not FDA-approved. |
| Sport | Athletes should check the current WADA prohibited list, which changes every year. |
Rules change. Check with the TGA (Australia), your local regulator, or WADA for sport.
Key references
- Jastreboff et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM, 2023.
General information, not advice. Talk to a qualified healthcare professional before starting, changing or stopping anything.